Filing Flows › Arbutus Biopharma (ABUS) › Q2 2026 › vs Q1 2026
Arbutus Biopharma (ABUS) Q2 2026 vs Q1 2026 (quarter over quarter)
Arbutus Biopharma's revenue fell $178M (-99%) from $179M in Q1 2026 to $1.0M in Q2 2026. The biggest changes: Revenue from collaborations and licenses −$178M (-100%); Collaborations and licenses −$2K (-1%); Non-cash royalty revenue −$1K (-0.6%).
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue from collaborations and licenses | $632K | $179M | −$178M | -100% |
| Collaborations and licenses | $202K | $204K | −$2K | -1% |
| Non-cash royalty revenue | $180K | $181K | −$1K | -0.6% |
| Revenue | $1.0M | $179M | −$178M | -99% |
| Other income, net | $821K | $787K | $34K | +4% |
| Net loss | $5.1M | −$170M | $175M | — |
| Costs & expenses | $7.0M | $180M | −$173M | -96% |
| Operating costs | $7.0M | $10.2M | −$3.2M | -32% |
| Research & development | $2.9M | $4.1M | −$1.2M | -30% |
| General & admin | $3.9M | $5.9M | −$2.0M | -34% |
| Other operating costs | $213K | $209K | $4K | +2% |
| Operating cash sources | $7.7M | $9.5M | −$1.8M | -19% |
| Depreciation & amortization | $11K | $11K | $0 | 0% |
| Share-based compensation | $1.6M | $1.4M | $266K | +20% |
| Cash used in operations | $6.0M | $8.1M | −$2.1M | -26% |
| Net loss absorbed | $5.1M | −$170M | $175M | — |
| Working capital & other | $2.5M | $179M | −$177M | -99% |
Questions
How much did Arbutus Biopharma's revenue grow quarter over quarter in Q2 2026?
Arbutus Biopharma's revenue fell $178M (-99%) from $179M in Q1 2026 to $1.0M in Q2 2026.
What drove Arbutus Biopharma's revenue change in Q2 2026?
Revenue from collaborations and licenses −$178M (-100%); Collaborations and licenses −$2K (-1%); Non-cash royalty revenue −$1K (-0.6%).